Biography for Tracy Staton
Tracy Staton, Senior Editor
Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at email@example.com or find her on LinkedIn.
Articles by Tracy Staton
Novartis and its Neupogen biosimilar are steamrolling toward the U.S. market. But Amgen hasn't given up stopping the product in its tracks. The biotech last week urged a California court to block the biosimilar launch, with FDA approval expected as soon as March 9.
Look for some big changes next time you run across a magazine ad for Crestor or Viagra or any of the brands on heavy rotation. The FDA has decided that its long-standing disclose-all policy on side effects was wrong. Way wrong.
Novo Nordisk has joined the spinoff club. The Danish drugmaker says it's ready to let its information technology unit, NNIT, go solo via an initial public offering.
Striking out in our CEO search? Not us, says Sanofi. Chairman Serge Weinberg says the board is talking to a "limited number of candidates" and expects to make a choice very soon. A choice, by the way, from outside Sanofi, Weinberg says.
Pfizer has snapped up Hospira, an injectables specialist, for $90 per share, or some $15 billion, plus debt assumption.
Merck's long-awaited insomnia drug Belsomra (suvorexant) has now hit pharmacy shelves in the U.S. The drug is a first-in-class sleep aid finally approved last year after an initial rejection by the FDA.
For the past couple of years, the pharma industry has had something of a reprieve from patent-cliff nightmares. But according to Moody's Investors Service, some companies face new threats to their sweet dreams.
Sanofi and MannKind heralded the launch of Afrezza today, as their inhaled insulin hit store shelves in the U.S. For MannKind, it's a vindication after years of development setbacks. For Sanofi, it's a chance to show that it can broaden its base of diabetes sales beyond the hypersuccessful Lantus.
Big Pharma has been hiring out all sorts of functions companies once did in-house: sales, manufacturing, and IT services, to name a few. But according to The Wall Street Journal, one of the fastest-growing fields for pharma contractors isn't any of these. It's drug safety.
Johnson & Johnson has fired back against former FDA chief David Kessler, who testified against the company last week in a Risperdal liability case. Kessler can't be trusted on drug safety, J&J's lawyers said, because he's a "hired gun" known for attacking drugmakers in court.